Literature DB >> 30517768

Synergistic interactions between NOD receptors and TLRs: Mechanisms and clinical implications.

Mikhail V Pashenkov1, Nina E Murugina1, Anna S Budikhina1, Boris V Pinegin1.   

Abstract

Interactions between pattern recognition receptors (PRRs) shape innate immune responses to particular classes of pathogens. Here, we review interactions between TLRs and nucleotide-binding oligomerization domain 1 and 2 (NOD1 and NOD2) receptors, two major groups of PRRs involved in innate recognition of bacteria. Most of experimental data both in vitro and in vivo suggest that NODs and TLRs synergize with each other at inducing the production of cytokines and antimicrobial peptides. Molecular mechanisms of this synergy remain poorly understood, although several scenarios can be proposed: (i) direct interactions of signaling pathways downstream of NODs and TLRs; (ii) mutual transcriptional regulation of unique components of NOD-dependent and TLR-dependent signaling pathways; and (iii) interactions at the post-transcriptional level. Potential practical implications of NOD-TLR synergy are dual. In sepsis, where synergistic effects probably contribute to excessive proinflammatory cytokine production, blockade of NOD1, and/or NOD2 in addition to TLR4 blockade may be required to achieve therapeutic benefit. On the other hand, synergistic combinations of relatively small doses of NOD and TLR agonists administered before infection could be used to boost innate resistance against bacterial pathogens. ©2018 Society for Leukocyte Biology.

Entities:  

Keywords:  NF-κB; NOD1; NOD2; TLR4; lipopolysaccharide; muramyl dipeptide; sepsis

Mesh:

Substances:

Year:  2018        PMID: 30517768     DOI: 10.1002/JLB.2RU0718-290R

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  11 in total

1.  Discovery of Pyrazolocarboxamides as Potent and Selective Receptor Interacting Protein 2 (RIP2) Kinase Inhibitors.

Authors:  Curt D Haffner; Adam K Charnley; Christopher J Aquino; Linda Casillas; Máire A Convery; Julie A Cox; Mark A Elban; Nicole C Goodwin; Peter J Gough; Pamela A Haile; Terry V Hughes; Beth Knapp-Reed; Constantine Kreatsoulas; Ami S Lakdawala; Huijie Li; Yiqian Lian; David Lipshutz; John F Mehlmann; Michael Ouellette; Joseph Romano; Lisa Shewchuk; Arthur Shu; Bartholomew J Votta; Huiqiang Zhou; John Bertin; Robert W Marquis
Journal:  ACS Med Chem Lett       Date:  2019-10-11       Impact factor: 4.345

2.  Toll-like Receptor 4-Independent Effects of Lipopolysaccharide Identified Using Longitudinal Serum Proteomics.

Authors:  Erin Harberts; Tao Liang; Sung Hwan Yoon; Belita N Opene; Melinda A McFarland; David R Goodlett; Robert K Ernst
Journal:  J Proteome Res       Date:  2020-02-24       Impact factor: 4.466

3.  SKAP2 suppresses inflammation-mediated tumorigenesis by regulating SHP-1 and SHP-2.

Authors:  Kurara Takagane; Michinobu Umakoshi; Go Itoh; Sei Kuriyama; Akiteru Goto; Masamitsu Tanaka
Journal:  Oncogene       Date:  2022-01-17       Impact factor: 9.867

4.  Immunoregulation of Ghrelin in neurocognitive sequelae associated with COVID-19: an in silico investigation.

Authors:  Cristina Russo; Giovanna Morello; Giuliana Mannino; Antonella Russo; Lucia Malaguarnera
Journal:  Gene       Date:  2022-06-06       Impact factor: 3.913

Review 5.  Innate control of adaptive immunity and adaptive instruction of innate immunity: bi-directional flow of information.

Authors:  Margaret M McDaniel; Hannah E Meibers; Chandrashekhar Pasare
Journal:  Curr Opin Immunol       Date:  2021-08-20       Impact factor: 7.486

6.  Human Toll-like Receptor 8 (TLR8) Is an Important Sensor of Pyogenic Bacteria, and Is Attenuated by Cell Surface TLR Signaling.

Authors:  Siv H Moen; Birgitta Ehrnström; June F Kojen; Mariia Yurchenko; Kai S Beckwith; Jan E Afset; Jan K Damås; Zhenyi Hu; Hang Yin; Terje Espevik; Jørgen Stenvik
Journal:  Front Immunol       Date:  2019-05-31       Impact factor: 7.561

Review 7.  RIPK2 as a New Therapeutic Target in Inflammatory Bowel Diseases.

Authors:  Hajime Honjo; Tomohiro Watanabe; Ken Kamata; Kosuke Minaga; Masatoshi Kudo
Journal:  Front Pharmacol       Date:  2021-04-14       Impact factor: 5.810

8.  Novel chimeric TLR2/NOD2 agonist CL429 exhibited significant radioprotective effects in mice.

Authors:  Ying Cheng; Jicong Du; Ruling Liu; Suhe Dong; Jianming Cai; Fu Gao; Cong Liu
Journal:  J Cell Mol Med       Date:  2021-02-19       Impact factor: 5.310

9.  Induction of Innate Immune Response by TLR3 Agonist Protects Mice against SARS-CoV-2 Infection.

Authors:  Hadas Tamir; Sharon Melamed; Noam Erez; Boaz Politi; Yfat Yahalom-Ronen; Hagit Achdout; Shlomi Lazar; Hila Gutman; Roy Avraham; Shay Weiss; Nir Paran; Tomer Israely
Journal:  Viruses       Date:  2022-01-19       Impact factor: 5.048

10.  A comprehensive interaction study provides a potential domain interaction network of human death domain superfamily proteins.

Authors:  Wei Zhou; Naoe Kaneko; Tomoya Nakagita; Hiroyuki Takeda; Junya Masumoto
Journal:  Cell Death Differ       Date:  2021-05-15       Impact factor: 15.828

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.